Divarasib + Sotorasib + Adagrasib
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Small Cell Lung Cancer
Conditions
Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer
Trial Timeline
Sep 23, 2024 → Nov 30, 2029
NCT ID
NCT06497556About Divarasib + Sotorasib + Adagrasib
Divarasib + Sotorasib + Adagrasib is a phase 3 stage product being developed by Chugai Pharmaceutical for Non-Small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06497556. Target conditions include Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06497556 | Phase 3 | Active |
Competing Products
20 competing products in Non-Small Cell Lung Cancer